Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0211

Scientific exchange · Dr. Quentin Eriksen

19 Feb 2026 · In person · Dr. Quentin Eriksen, Policlinico Gemelli · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0211—

Capture insight from this engagement

Location: Policlinico Gemelli
Therapeutic area: Neurology
Country: Italy
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Switching between CGRP agents
Real-world persistence

Scientific content used

LMV persistence data summary
CGRP class review

Questions raised

No questions recorded.

Notes

Scientific exchange with headache specialist at Policlinico Gemelli. Discussed switching between cgrp agents, real-world persistence.

Insights captured (1)

Capture insight

INS-0051Critical
Switching between CGRP agents
Switching between CGRP agents: request for data reported by headache specialist (IT).
Action in progress

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Schedule follow-up in 6 weeks

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 5
Depth of exchange: 5
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0211

Audit history (0)

All create, update and approval events for this record

No audit events in sample data